Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of Safety, Tolerance and Immunogenicity of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

NCT05408312 is registered in ClinicalTrials.gov with National Vaccine and Serum Institute, China as lead sponsor.

NCT NCT05408312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05408312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of Safety, Tolerance and Immunogenicity of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above
Lead sponsor
National Vaccine and Serum Institute, China
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2022
Completion date
February 28, 2024
Enrollment
234 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia